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Abstract
With the growing epidemic of obesity across the United States, adolescents and adults are using
dietary supplements for the purpose of weight loss and to build muscle with the common
misconception that these supplements are proven safe and effective by the government before
they are available to consumers (Pomeranz, Barbosa, Killian, & Austin, 2015). Since
supplements with ephedrine are no longer allowed on the market due to serious health risks,
manufacturers have reformulated their supplements to include ingredients that have a similar
chemical structure and pharmacological properties as ephedrine and have advertised them as
“ephedra-free” (Foster, 2013). There is very limited national data available identifying
associated risks or adverse events with ephedra-free supplements. This became an area of
clinical interest after a 20 year old female college student presented to the family planning office
requesting to initiate an oral contraceptive and had reported the occasional use of over-thecounter ephedra-free Xendarine for weight loss. Her body mass index (BMI) indicated she was
underweight; she had no previous medical history, an unremarkable family history, and the
review of systems and physical examination was negative for any abnormal or pertinent findings.
A literature review was conducted to identify what potential health risks have been associated
with the use of ephedra-free weight loss products, which included randomized controlled trials
and numerous case reports. The research findings will be discussed, as they identify a strong
association of serious cardiovascular and neurological health risks with prolonged use of
ephedra-free weight loss products.
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Potential Health Risks Associated with the Use of OTC Ephedra-Free Weight Loss Products
Background
Significant attention has been placed on the growing epidemic of obesity, which is
defined as a body mass index (BMI) of 30 or greater. Across the United States (U.S.), the Center
for Disease Control and Prevention (CDC) has estimated a prevalence of obesity of
approximately 25% or greater across a majority of the states (Moaaddeb, Tofade, & Bevins,
2011). With the expanding and readily available weight loss or dietary supplements advertised
across numerous forms of media and sold over-the-counter (OTC) in various stores and online,
more adolescents and adults are purchasing these supplements to assist with their personal
weight loss goals and/or to build more muscle. In fact, studies conducted among adults in the
U.S. have identified that 17% have used supplements to improve their sports performance, while
20.6% of women and 9.7% of men have used supplements advertised specific for weight loss
(Pomeranz, Barbosa, Killian, & Austin, 2015). In addition, a national survey conducted in 2002
revealed that 29.1% of adolescents and young adults between the ages of 14 and 19 years of age
reported using any form of dietary supplement within the last 30 days, while 10.7% reported a
history of using dietary supplements for weight loss at some point (Pomeranz, Barbosa, Killian,
& Austin, 2015). Unfortunately, the growing use of dietary supplements across the U. S. is
perpetuated by consumers misconception regarding their safety and efficacy, which is greatly
highlighted by a national study identifying that two-thirds of its respondents believed that these
supplements were not only safe and effective, but half of those respondents also believed these
supplements were proven safe and effective by the federal government before being placed on
the market (Pomeranz, Barbosa, Killian, & Austin, 2015).
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As a result of Congress passing the Dietary Supplement Health and Education Act
(DSHEA) in 1994, the Food and Drug Administration (FDA) is no longer required to regulate or
allowed to verify the safety or efficacy of any dietary supplement before it is placed on the
market. This has contributed to an industry with a growth of $32 billion a year. The
responsibility of verifying the safety of these dietary supplements is placed on the manufacturers
and their adherence to good manufacturing practices. These manufacturers are only required to
report any serious adverse events that result in hospitalization, disability or death (Pomeranz,
Barbosa, Killian, & Austin, 2015). A review of available national surveillance data obtained
from 63 emergency departments (ED) from 2004 to 2013 revealed “an estimated 23,000
emergency department visits in the United States every year are attributed to adverse events
related to dietary supplements” (Geller et al., 2015, p. 1531), and of those adverse events, weight
loss supplements account for 25.5% and involve cardiovascular manifestations of palpitations,
tachycardia, and chest pain (Geller et al., 2015). Potentially contributing to the limited national
data on associated adverse events, healthcare providers are not always aware that their patients
are consuming dietary supplements, nor do consumers associate any symptoms to these
supplements, so most adverse events are never reported to the FDA (Geller et al., 2015; &
Pomeranz, Barbosa, Killian, & Austin, 2015).
Relative to this clinical topic, a 20 year old female college student presented as a new
patient to the family planning office requesting to start an oral contraceptive. She had no past
medical history, and family history was negative for any clotting disorders, heart disease,
neurological disorders or cancer. Upon review of her current medications, she reported the use
of OTC multivitamin, Midol as needed for menstrual cramps, Tylenol as needed for headaches,
and ephedra-free Xenadrine occasionally for weight loss as needed. Her body mass index of

POTENTIAL HEALTH RISKS ASSOCIATED WITH THE USE OF

6

17.2 indicated she was underweight, and she denied any associated symptoms or side effects
related to this weight loss supplement. Vital signs were all within normal limits and physical
examination was negative for any pertinent or abnormal findings. Due to safety concerns and
unknown potential health risks regarding dietary supplements, she was instructed to discontinue
use of Xenadrine. With the federal government banning ephedrine-containing dietary
supplements from the market in April 2004 due to the serious adverse events, this case highlights
the need for research to identify any reported adverse events or potential health risks that have
been associated with the use of OTC ephedra-free weight loss supplements (Stephensen &
Sarlay, 2009). Pertinent research findings will improve clinical awareness, knowledge, and
competency regarding the use of these weight loss supplements in order to provide current and
appropriate patient education regarding its use, appropriate monitoring should patients choose to
continue to use these supplements despite medical advice, and improve reporting of adverse
events to the FDA.
Case Report
Presenting as a new patient to the family planning office, L. J. is a 20 year old female
requesting to start oral contraceptives to prevent unplanned pregnancies. Upon review, her past
medical history is negative for any medical conditions, surgeries, or hospitalizations. Allergies
include penicillin, and her current medication list includes the following: over-the-counter (OTC)
ephedra-free Xenadrine as needed for weight loss; OTC multivitamin occasionally; OTC Midol
for menstrual cramps as needed; and OTC Tylenol as needed for headaches. She is up to date on
recommended vaccinations, including the Human Papillomavirus (HPV) vaccine series. Her
reported reproductive history includes a menstrual cycle occurring every month and lasting about
5 days in length without any heavy clots, and a last menstrual cycle that occurred on January 19,
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2016. She denies any history of pregnancies, any previous screenings or treatments for sexuallytransmitted infections (STIs), or any previous use of prescribed contraceptives. She is
heterosexual, is currently sexually active with the occasional use of condoms as a barrier method,
and reports utilizing the emergency contraceptive Plan B once around this last New Years.
Family history includes the following: hyperlipidemia and benign breast mass removed about 1
year ago in her mother; blood clot following surgery in her father; no medical conditions among
siblings (brother & sister); and no family history of clotting disorders. Social history includes
the following: currently attending college; single; denies any use of tobacco products or exposure
to second hand tobacco smoke; reports current alcohol use of about 3 weekends per month with
2-5 mixed drinks each time; and reports regular physical exercise daily.
Measured vital signs were as follows: height of 67 inches; weight of 110 lbs (50 kg);
blood pressure of 112/74; heart rate of 82; respiratory rate of 18; temperature of 98.5 F; and BMI
of 17.2 (underweight). Review of systems revealed whitish vaginal discharge without odor
occasionally, but was otherwise proved negative for any other symptoms. Upon physical
examination, patient was alert, oriented x 3, affect stable, pleasant, cooperative, well-developed,
well-nourished, and in no acute distress. Examination of eyes revealed the following: pupils
were equal, round, and reactive to light (PEERL); extraocular movements were intact (EOMI);
and no discharge or erythema were noted. Heart rate and rhythm were regular without murmur,
gallop or rub. Lung sounds were clear bilaterally without rales, rhonchi, or wheezing noted and
breathing was unlabored. Abdomen was flat, non-distended, and non-tender without any
guarding, masses, organomegaly, and bowel sounds were normoactive in all 4 quadrants.
Laboratory testing included urine pregnancy test to verify pregnancy status prior to
initiating oral contraception, as well as annual screening for chlamydia and gonorrhea per
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clinical screening guidelines. Diagnoses included initial encounter and prescription for
contraceptives, negative pregnancy test, screenings for bacterial sexually transmitted infections
(STIs), and high risk heterosexual behavior. Documented counseling that occurred during
encounter included family planning and forms of available contraception with risks and benefits
of each method, education and prevention of STIs, healthy body mass index (BMI), healthy
dietary and lifestyle modifications to maintain healthy weight and general health, and potential
risks related to use of over-the-counter weight loss supplements.
With confirmation of negative pregnancy test and no identified risks factors or
contraindications, an oral monophasic combined oral contraceptive (COC) was initiated per
patient’s preference. She was instructed to use condoms as a barrier method for the first week of
oral contraceptive, as well as with all sexual encounters for STI prevention. Patient will be
contacted regarding results of STI screenings when made available. She was instructed to
monitor for signs of abdominal pain, chest pain, headaches, visual changes/disturbances, or
severe leg pain due to risks of blood clots while taking COCs, and to seek medical attention if
these symptoms should develop. Common side effects or reactions that may occur and should
resolve were discussed and included nausea, vomiting, breast tenderness, and bleeding
irregularities. Discussed clinical recommendations for cervical screenings after the age of 21
years old, and monthly self-breast examinations were recommended for her own body
awareness. Encouraged to continue regular physical activity, maintain a well-balanced meal and
adequate hydration in regards to overall health and weight management. Informed of current
BMI, which indicates she’s underweight, and highly encouraged to discontinue the use OTC
Xenadrine due to potential health risks. Tobacco use was discussed and highly discouraged, as
well as encouraged to limit alcohol use due to identified high risk sexual behaviors and safety

POTENTIAL HEALTH RISKS ASSOCIATED WITH THE USE OF

9

concerns correlated with excessive alcohol intake. Will complete a follow-up appointment in
three months to evaluate adherence and adjustment to medication, as well as discuss any
questions, concerns, or side effects, and will anticipate scheduling an annual physical
examination with clinical Pap smear and breast examination after reaches 21 years of age in 1
year.
Literature Review
As health care providers, it is our responsibility to initially evaluate the quality of
research prior to implementing it into our clinical practice. To assist with evaluating various
studies and research, the evidence-leveling system created by the American Association of
Critical Care Nurses (AACN) in 2008-2009 was used in this process, which identifies six
separate levels of evidence with Level A as the highest level of evidence (e.g. meta-analysis and
meta-synthesis) and Level M as the lowest level of evidence (e.g. manufacturer
recommendations) (Armola et al., 2009). Each research study that is discussed will have a level
of evidence identified.
Online resources available through the University of North Dakota’s (UND) Harley E.
French Library of the Health Sciences was utilized to complete the online literature search
required to address the identified area of clinical interest and included CINAHL, PubMed, and
the Cochrane Library. The main concepts or terms utilized during this literature search included
“ephedra-free”, “weight loss products”, and “weight loss products, dietary supplements”;
however, the term “ephedra-free” produced more specific results, and due to limited available
data, no additional limitations in regards to date of publication, etc., were applied. At the
conclusion of this literature search, fourteen research articles, including 3 randomized clinical
trials (Level B evidence) and 11 case reports (Level E evidence) were identified as applicable to
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the chosen research question of: what potential health risks have been associated with the use of
OTC ephedra-free weight loss products.
This area of clinical interest was deemed pertinent upon completing an initial encounter
with a 20 year old female college student that had presented as a new patient to the family
planning office requesting to start an oral contraceptive. With the patient’s medical history,
family history, review of systems and physical examination unremarkable for any pertinent
findings or contraindications, an oral contraceptive was initiated. However, the occasional use of
OTC ephedra-free Xendarine was reported upon review of her current medications, which she
believed were safe to consume and had denied any associated symptoms or side effects. With
the well-known banning of ephedrine-containing dietary supplements from the market in 2004
due to its serious adverse events, this case highlights the need for further research to identify any
reported adverse events or potential health risks that have been associated with the use of OTC
ephedra-free weight loss supplements in order to improve clinical awareness, knowledge, and
competency regarding the use of these weight loss supplements to provide current and
appropriate patient education regarding its use, monitoring should patients choose to continue
these supplements despite medical advice, and improve reporting of adverse events to the FDA.
As mentioned previously, manufacturers of dietary supplements are no longer allowed to
produce products containing the ingredient ephedrine due to the serious cardiovascular and
neurological risks and adverse events that were identified. This resulted in the production of
“ephedra-free” supplements using a combination of ingredients, such as guarana, bitter orange or
Citrus aurantium, ma huang, cocoa, Coleus forskolii and synephrine as substitutes for ephedrine.
These ingredients have been found to have similar chemical and pharmacological properties as
its predecessor ephedrine, yet there has been few research studies that have evaluated the safety
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of these products (Foster et al., 2013; Moaddeb, Tofade, & Bevins, 2011; Retamero, Rivera, &
Murphy, 2011).
Unfortunately, only a few randomized controlled trials (RCTs) have been conducted to
determine the adverse effects of ephedra-free weight loss supplements required to provide
sufficient evidence to prove their efficacy and safety. Results from a RCT published in 2005
determined there was no significant change in either blood pressure or systemic vascular
resistance index (SVRI) among healthy volunteers that were administered a single dose of
Metabolife Ephedra-Free (Min, McBride, Kardas, Ismali, Sinha, Kluger, & White, 2005). In
contrast, significant increases in blood pressure measurements and irregular atrial/ventricular
events were noted on an electrocardiograph (ECG) compared to baseline readings following the
administration of multiple daily doses of several different ephedra-free products, as evidenced by
two additional randomized studies (Foster et al., 2013; & Haller, Benowitz, & Jacob, 2005).
Other associated symptoms included nausea and vomiting that were linked to a heavy
contamination of bacillus species among two separate supplements (Foster, 2013). These
“findings suggests that prolonged use of certain “ephedra-free” supplements may alter cardiac
electrophysiology” compared to a one-time dose, as well as have the potential risks associated
with herb-drug interactions and microbial contamination (Foster et al., 2013, p 271).
Furthermore, numerous case reports of associated adverse effects of rhabdomyolysis,
psychosis, hypertensive urgency with presenting blood pressure of 234/130, malignant
hypertension with aortic dissection, malignant hypertension with hypertensive retinopathy,
ventricular fibrillation, ST-segment elevation myocardial infarction, exercise-induced syncope
with QT prolongation, left middle cerebral artery vasospasm with stroke, and ischemic stroke
have been associated with ephedra-free supplements since they became available to consumers.
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In most of these cases, symptoms related to the adverse event developed after consuming the
supplements for a prolonged period of time that ranged from a couple of weeks to numerous
months. Among these reported cases, most had no predisposing medical history that would have
accounted for or contributed to the development of these adverse events, and symptoms resolved
without recurrence after the discontinuation of the ephedra-free supplement. In these patient
cases, the probability that the adverse events were, indeed, associated with the patient’s reported
use of an ephedra-free supplement prior to the onset of symptoms was established with the use of
the clinical tool Naranjo adverse drug reaction probability scale (Ahmed, 2009; Bouchard,
Howland, Greller, Hoffman, & Nelson, 2005; Burke, Seda, Allen, & Knee, 2007; Carol, 2013;
Holmes & Tavee, 2008; Moaddeb, Tofade, & Bevins, 2011; Nasir, Durning, Fergunson, Barold,
& Haigney, 2004; Retamero, Rivera, & Murphy, 2011; Stephenson & Sarlay, 2009; Thomas,
Munir, McIntyre, & Ferguson, 2009; & Willis, Moawad, Hartzell, Iglesias, & Jackson, 2006).
Even though case reports have limited ability to identify causation, the pertinent research
findings gained from the available randomized controlled trials (RCTs) and numerous case
reports found in medical literature establish a strong association of serious cardiovascular and
neurological health risks with the prolonged use of ephedra-free weight loss supplements or
products that are similar to those previously reported with ephedrine, which has clinical
implications for the safety of its consumers and our patients.
Learning Points
In conclusion, research findings have established a strong association of serious
cardiovascular and neurological health risks with the prolonged use of ephedra-free weight loss
supplements or products. It is the responsibility and recommendation for all healthcare providers
to ask patients about their use of supplements and document with each encounter, as well as
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provide education regarding the use of dietary supplements and associated health risks that have
been identified. Since the Food and Drug Administration (FDA) is no longer required or allowed
to verify the safety and efficacy of dietary supplements before they are released on the market, it
is imperative that healthcare providers continue to monitor and report any adverse events to the
FDA, which can be completed online through the adverse event reporting program known as
MedWatch located on the FDA’s website. Increased reporting of adverse events will not only
help the FDA identify any safety risks related to these supplements, but it also provides the
opportunity to help advocate for improved regulation of dietary supplements by the FDA.
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